EyePoint Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 2/4
EyePoint Pharmaceuticals CEO'su Jay Duker, Jan2023 tarihinde atandı, in görev süresi 1.83 yıldır. in toplam yıllık tazminatı $ 2.92M olup, şirket hissesi ve opsiyonları dahil olmak üzere 21.1% maaş ve 78.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.089% ine doğrudan sahiptir ve bu hisseler $ 702.73K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 3.3 yıldır.
Anahtar bilgiler
Jay Duker
İcra Kurulu Başkanı
US$2.9m
Toplam tazminat
| CEO maaş yüzdesi | 21.1% |
| CEO görev süresi | 1.8yrs |
| CEO sahipliği | 0.09% |
| Yönetim ortalama görev süresi | 1.8yrs |
| Yönetim Kurulu ortalama görev süresi | 3.3yrs |
Son yönetim güncellemeleri
Recent updates
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%
Oct 29
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Sep 13EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Aug 29These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Aug 15EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Jun 19EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$79m |
| Dec 31 2023 | US$3m | US$614k | -US$71m |
| Sep 30 2023 | n/a | n/a | -US$100m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$102m |
| Dec 31 2022 | US$2m | US$515k | -US$102m |
| Sep 30 2022 | n/a | n/a | -US$78m |
| Jun 30 2022 | n/a | n/a | -US$77m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$3m | US$269k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$54m |
| Jun 30 2021 | n/a | n/a | -US$42m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$53k | n/a | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$52m |
| Mar 31 2020 | n/a | n/a | -US$51m |
| Dec 31 2019 | US$80k | n/a | -US$57m |
| Sep 30 2019 | n/a | n/a | -US$58m |
| Jun 30 2019 | n/a | n/a | -US$75m |
| Mar 31 2019 | n/a | n/a | -US$98m |
| Dec 31 2018 | US$27k | n/a | -US$86m |
Tazminat ve Piyasa: Jay 'ın toplam tazminatı ($USD 2.92M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 3.21M ).
Tazminat ve Kazançlar: Jay şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Jay Duker (65 yo)
1.8yrs
Görev süresi
US$2,915,146
Tazminat
Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. He served as C...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 1.8yrs | US$2.92m | 0.089% $ 702.7k | |
| Executive VP & CFO | 5yrs | US$1.78m | 0.070% $ 551.3k | |
| Interim Head of R&D and Director | less than a year | US$161.67k | 0.017% $ 132.4k | |
| Senior Vice President of Manufacturing & Operations | 1.3yrs | Veri yok | Veri yok | |
| Chief Legal Officer & Company Secretary | 6yrs | Veri yok | Veri yok | |
| Chief People Officer & Senior VP of IT | 5.8yrs | Veri yok | Veri yok | |
| Senior VP & Chief Commercial Officer | 5.4yrs | US$1.46m | 0% $ 0 | |
| Chief Business Officer | 1.1yrs | US$1.61m | 0.020% $ 158.7k | |
| Chief Regulatory Officer | 2.7yrs | Veri yok | Veri yok | |
| Senior VP and Head of Development & Program Management | 1.3yrs | Veri yok | Veri yok | |
| Chief Medical Officer | less than a year | Veri yok | Veri yok | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | Veri yok |
1.8yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim: EYPT 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 1.3yrs | US$2.92m | 0.089% $ 702.7k | |
| Interim Head of R&D and Director | 6.1yrs | US$161.67k | 0.017% $ 132.4k | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | Veri yok | |
| Independent Non-Executive Chairman | 6.4yrs | US$214.78k | 0.019% $ 152.6k | |
| Independent Director | 5.3yrs | US$171.67k | 0.015% $ 115.7k | |
| Vice Chair | 8.2yrs | US$3.74m | 0.33% $ 2.6m | |
| Co- Chairman of Scientific Advisory Board | 3.3yrs | Veri yok | Veri yok | |
| Member of Executive Scientific Advisory Board | 3.3yrs | Veri yok | Veri yok | |
| Independent Director | 2.3yrs | US$149.17k | 0.024% $ 191.6k | |
| Co-Chair of Scientific Advisory Board | 3.3yrs | Veri yok | Veri yok | |
| Member of Executive Scientific Advisory Board | 3.3yrs | Veri yok | Veri yok | |
| Member of Executive Scientific Advisory Board | 3.3yrs | Veri yok | Veri yok |
3.3yrs
Ortalama Görev Süresi
66yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: EYPT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).